Drugs / LCAR-AIO
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06866080 | Jun 2025 | — | Nanjing Legend Biotech Co. | Withdrawn | No outcome recorded |
| Phase 0 | NCT06653556 | Jan 2025 → Sep 2027 expected | systemic lupus erythematosus | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT06869278 | Jun 2025 | multiple sclerosis, myasthenia gravis, myelin oligodendrocyte glycoprotein antibody-associated disease, neuromyelitis optica | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Withdrawn | No outcome recorded |
| Phase 1 | NCT05318963 | Mar 2022 → Jan 2025 | B-cell non-Hodgkin lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Terminated | No outcome recorded |
| Phase 1 | NCT05292898 | Mar 2022 → Jan 2025 | precursor B-cell acute lymphoblastic leukemia | Institute of Hematology & Blood Diseases Hospital, China | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCAR-AIO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06866080 ↗ |
| Known as | LCAR-AIO Cells | “Each subject will be treated with LCAR-AIO Cells” NCT05292898 ↗ |
| Modality | Cell therapy | “a triple-targeted cell preparation” NCT05292898 ↗ |
| Route | Other | “LCAR-AIO infusion” NCT06653556 ↗ |